OCT1 polymorphisms may affect the pharmacokinetics of other opioids beyond morphine and its pro-drug codeine, as we previously reported for O-desmethyltramadol, the active metabolite of tramadol [27]. Consequently, carriers of loss-of-function OCT1 polymorphisms may be at increased risk of adverse...